Presentatie - vzw farmaka asbl
Presentatie - vzw farmaka asbl
Presentatie - vzw farmaka asbl
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ACE-inhibitoren<br />
71. Danchin. Arch Intern Med 2006;166:787-96<br />
Design N/n Population Sd Interventions Outcomes Results<br />
MA N=7,<br />
n=33<br />
960<br />
- Evidence of<br />
CAD<br />
-High cv risk<br />
- No cardiac<br />
failure or left<br />
ventricle<br />
dysfunction<br />
-80% male<br />
-39 to 70%<br />
previous MI<br />
4.4y -ACE-inhibitor<br />
(enalapril,<br />
perindopril,<br />
quinapril,<br />
ramipril or<br />
trandolapril)<br />
-placebo<br />
All cause death OR= 0.86 (95%CI 0.79 to 0.93)<br />
Cardiovascular death OR= 0.81 (95%CI 0.73 to 0.90)<br />
MI OR= 0.82 (95%CI 0.75 to 0.89)<br />
Stroke OR= 0.77 (95%CI 0.66 to 0.88)<br />
www.<strong>farmaka</strong>.be<br />
Project<br />
Farmaka
Change language